New hope for patients with allergic respiratory diseases, scientists from the CNRS (National Center for Scientific Research), Inserm and the University of Toulouse III – Paul Sabatier have recently discovered a molecule that plays a key role in triggering inflammation that causes allergic respiratory diseases such as asthma and allergic rhinitis.
This molecule, named TL1A, belongs to the alarmin family and represents a therapeutic target of major interest for the treatment of these conditions.
The study, led by Corinne Cayrol and Jean-Philippe Girard, was published in the Journal of Experimental Medicine. According to the CNRS, treatments based on antibodies blocking TL1A could benefit patients suffering from severe asthma or other allergic diseases in the years to come.
In France, at least 17 million people are affected by allergic diseases, and the most serious forms of asthma cause several hundred deaths each year, according to Public Health France.
 Sophie de Duiéry
|
11/04/2024 | 
